Financial Data and Key Metrics Changes - Sales in Q3 2025 were $1.03 billion, reflecting a 6% increase in local currency and an 8% increase on a U.S. dollar reported basis [6][9] - Adjusted EPS for the quarter was $11.15, a 9% increase over the prior year, while reported EPS was $10.57 compared to $9.96 in the prior year [8][9] - Gross margin was 59.2%, a decrease of 80 basis points primarily due to tariff costs [7][8] - Adjusted operating profit amounted to $309.9 million, up 5% versus the prior year, with an adjusted operating margin of 30.1% [7][8] Business Line Data and Key Metrics Changes - Laboratory sales increased 4%, Industrial sales increased 9% (10% excluding acquisitions), and Product Inspection grew 7% [6][7] - Service revenue grew 8% in the quarter, including a 1% benefit from acquisitions [7] - Food Retail sales grew 5% against easy year-ago comparisons [7] Market Data and Key Metrics Changes - Local currency sales increased 10% in the Americas, 6% in Europe, and 1% in Asia [6] - Local currency sales in China increased 2% during the quarter, marking the first growth in the Industrial business in over two years [19][49] Company Strategy and Development Direction - The company is focused on capturing growth opportunities in automation, digitalization, and onshoring, while remaining agile amid global trade uncertainties [4][11] - Recent acquisitions aim to enhance North American distribution and service capabilities, contributing modestly to sales growth [10][15] - The company continues to invest in innovation and digital capabilities to improve customer productivity and insights [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating market uncertainties and highlighted the importance of innovation and operational excellence [4][20] - The outlook for 2026 anticipates local currency sales growth of approximately 4%, with expectations of gradual improvement in market conditions [23][24] - Management noted that while short-term uncertainties persist, the company is well-positioned to gain market share through its innovative portfolio [24][60] Other Important Information - The company expects local currency sales growth of approximately 3% for Q4 2025, with adjusted EPS guidance in the range of $12.68-$12.88 [12][13] - Tariff costs are projected to have a gross headwind of approximately 7% on EPS for Q4 2025 [12][13] Q&A Session Summary Question: Can you provide a breakdown of the 2026 guidance by segment, particularly for industrial? - Management expects low to mid-single digit growth in the Laboratory business and similar growth in core Industrial and Product Inspection segments [27] Question: How is the consumer market affecting consumer-facing segments like PID? - Management noted that while the end market remains challenging, recent product innovations have been well received, particularly in the middle market [29][30] Question: What are the expectations for onshoring demand in 2026 versus 2027? - Management believes the company is well-positioned to benefit from onshoring activities, but expects a gradual impact over the coming years [44][45] Question: What are the growth expectations for China in the lab and industrial sectors? - Management anticipates low single-digit growth in both sectors, with optimism for medium to long-term opportunities in the lab sector [48][49] Question: Can you elaborate on the recent acquisitions and their impact? - The company completed several small acquisitions to enhance distribution and service capabilities, contributing less than 1% to sales growth [53][54]

Financial Data and Key Metrics Changes - Sales for Q3 2025 were $1.03 billion, reflecting an 8% increase on a reported basis and a 6% increase in local currency, with a 5% increase excluding recent acquisitions [6][9] - Adjusted EPS for the quarter was $11.15, a 9% increase over the prior year, while reported EPS was $10.57 compared to $9.96 in the prior year [8][9] - Gross margin decreased to 59.2%, down 80 basis points primarily due to tariff costs [7] Business Line Data and Key Metrics Changes - Laboratory sales increased by 4%, while industrial sales grew by 9%, with core industrial growing 10% excluding acquisitions [6][7] - Product inspection sales grew by 7%, and food retail sales increased by 5% [6][7] - Service revenue grew by 8%, including a 1% benefit from acquisitions [7] Market Data and Key Metrics Changes - Local currency sales growth by region showed a 10% increase in the Americas, 6% in Europe, and 1% in Asia [6] - Sales in China increased by 2% during the quarter, marking the first growth in the industrial business in over two years [19][49] Company Strategy and Development Direction - The company is focused on capturing growth opportunities in automation, digitalization, and onshoring, while remaining agile amid global trade uncertainties [4][11] - Recent acquisitions aim to enhance North American distribution and expand life science equipment offerings, contributing modestly to sales growth [10][15] - The company continues to invest in innovation and digital capabilities to improve customer insights and productivity [21][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating market uncertainties and highlighted the importance of innovation and operational excellence [4][20] - The outlook for 2026 anticipates local currency sales growth of approximately 4%, with expectations of gradual improvement in market conditions [23][14] - Management noted that while short-term uncertainties persist, the company is well-positioned to gain market share through its innovative portfolio [24][60] Other Important Information - The company expects local currency sales growth of approximately 3% for Q4 2025, with adjusted EPS guidance in the range of $12.68-$12.88 [12][13] - Tariff costs are projected to have a gross headwind of approximately 7% on EPS for Q4 2025 [12][13] Q&A Session Summary Question: Can you provide a breakdown of the 2026 guidance by segment, particularly for industrial? - Management expects low to mid-single digit growth in laboratory and industrial businesses, with modest benefits from recent acquisitions [27] Question: How is the consumer market affecting the PID segment? - Management noted that while the end market remains challenging, recent innovations have been well-received, particularly in the middle market [29] Question: What is the outlook for onshoring demand? - Management believes the company is well-positioned to benefit from onshoring activities, but expects a gradual impact over the coming years [44] Question: What are the expectations for growth in China? - Management anticipates low single-digit growth in both lab and industrial segments in China for the upcoming year [48] Question: Can you elaborate on the recent acquisitions? - The company completed several small acquisitions to enhance distribution and service capabilities, contributing less than 1% to sales growth [53][54]

Financial Data and Key Metrics Changes - Sales for Q3 2025 were $1.03 billion, reflecting an 8% increase on a reported basis and a 6% increase in local currency, with a 5% increase excluding recent acquisitions [6][10] - Adjusted EPS for the quarter was $11.15, a 9% increase over the prior year, while reported EPS was $10.57 compared to $9.96 in the prior year [9][10] - Gross margin decreased to 59.2%, down 80 basis points primarily due to tariff costs [7][9] - Adjusted operating profit was $309.9 million, up 5% year-over-year, with an adjusted operating margin of 30.1%, a decrease of 100 basis points [8][9] Business Line Data and Key Metrics Changes - Laboratory sales increased by 4%, while industrial sales grew by 9%, with core industrial growing 10% excluding acquisitions [6][8] - Product inspection sales grew by 7%, and food retail sales increased by 5% [6][8] - Service revenue grew by 8%, including a 1% benefit from acquisitions [6][8] Market Data and Key Metrics Changes - Local currency sales growth by region showed a 10% increase in the Americas, 6% in Europe, and 1% in Asia [6][10] - Local currency sales in China increased by 2% during the quarter [6][10] Company Strategy and Development Direction - The company is focused on capturing growth opportunities in automation, digitalization, and onshoring, while remaining agile amid global trade uncertainties [4][12] - Strategic initiatives include investments in innovation and operational excellence to navigate challenging market conditions [4][21] - The company plans to continue using free cash flow primarily for share repurchases and small acquisitions, with an additional $2.75 billion authorized for the share repurchase program [16][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to capture growth despite uncertainties in global trade and governmental policies [4][12] - The outlook for 2026 anticipates local currency sales growth of approximately 4%, with adjusted EPS forecasted to be in the range of $45.35-$46, representing an 8%-9% growth rate [14][15] - Management noted that while market conditions remain challenging, there is potential for gradual improvement and increased replacement demand [23][24] Other Important Information - The company completed several small acquisitions totaling approximately $75 million, which are expected to contribute modestly to sales growth [11][16] - Free cash flow for the first nine months was $689.5 million, a 6% increase on a per-share basis [11] Q&A Session Summary Question: Can you provide a breakdown of the 2026 guidance by segment, particularly around the industrial side? - Management expects low to mid-single digit growth in the laboratory business, with core industrial and product inspection also projected to grow low to mid-single digits [28] Question: How is the consumer market affecting the more consumer-facing segments? - Management noted that while the end market remains challenging, recent product innovations have been well received, particularly in food manufacturing [30] Question: What are the expectations for onshoring demand in 2026 versus 2027? - Management believes the company is well positioned to benefit from onshoring activities, but expects a gradual impact over the coming years [42] Question: What is the outlook for the lab and biopharma side in China? - Management anticipates low single-digit growth in both lab and industrial businesses in China, with some upside potential from recent updates in the Pharmacopia [46] Question: Can you elaborate on the recent acquisitions and their impact? - Management explained that the acquisitions were aimed at expanding distribution and service capabilities, with a focus on enhancing the life science equipment portfolio [52]